Strategic Intent: Praxis CEO On Unlearning, AI And Launching Two Neuroscience Drugs At Once
Strategic Intent: Praxis CEO On Unlearning, AI And Launching Two Neuroscience Drugs At Once
Praxis Precision Medicines is within weeks of FDA decisions on two potential firsts: relutrigine for SCN2A and SCN8A developmental and epileptic encephalopathies, and ulixacaltamide for essential tremor. In this episode of Strategic Intent, In Vivo senior reporter David Wild talks with Praxis CEO Marcio Souza about the company’s philosophy of “unlearning,” how AI is embedded across the organization, and why he believes neurology is entering its own precision medicine era. Souza also explains how
AI 伴隨問答
針對這篇報導有疑問?可直接點選快捷問題或向 AI 追問背景脈絡與技術細節:
Podcast 專家音訊節目
收錄於 888news Podcast 智庫專區,包含精華摘要與上市公司即時行情
Praxis Precision Medicines is within weeks of FDA decisions on two potential firsts: relutrigine for SCN2A and SCN8A developmental and epileptic encephalopathies, and ulixacaltamide for essential tremor. In this episode of Strategic Intent, In Vivo senior reporter David Wild talks with Praxis CEO Marcio Souza about the company’s philosophy of “unlearning,” how AI is embedded across the organization, and why he believes neurology is entering its own precision medicine era. Souza also explains how Praxis is preparing to launch two very different products at once, how he led the team through the vormatrigine setback, and what it takes to build a next-generation CNS company. Subscribe to the In Vivo and Scrip channels for more Strategic Intent.